SK bioscience To Advance Gates MRI’s Novel RSV Antibody Contender
SK bioscience jumps into RSV preventive antibody space through new Gates alliance.
Scrip - February 4, 2026

Amgen’s Revenue Gains Outweigh News That FDA Wants Tavneos Pulled From Market
Investors appeared not to be bothered by Amgen’s Q4 product updates, including the US FDA’s request to pull rare disease drug Tavneos from the market and discontinuation of Phase III bemarituzumab.
Scrip - February 4, 2026

Multiple Injuries Associated With Early Alert For Certain Abiomed Impella Heart Pumps
The US FDA says Abiomed has reported 22 serious injuries linked to an issue with some of its temporary heart pumps that provide support to patients with acute right heart failure.
Medtech Insight - February 3, 2026

BCI Developer INBRAIN Races Ahead With Bidirectional Chip, Merck Commercialization Letter, Trial
INBRAIN unveiled a bidirectional "rice-sized" BCI chip partnership, Merck commercialization progress and new speech-decoding trial in France as it advances its graphene-based cortical interface toward commercialization, pending regulatory clearance.
Medtech Insight - February 3, 2026

Stryker Elevates Spencer Stiles To President, COO As Scale And Tariffs Shape Outlook
Stryker’s leadership transition and operational execution were in focus during the company’s latest earnings call, as executives outlined changes to senior management, progress on margins amid tariff pressures, and confidence in sustained organic growth.
Medtech Insight - February 3, 2026

Super Bowl LX Ads: E.l.f. Kicks Off Telenovela; Dove Revisits Body Positivity; More
For Super Bowl LX on Feb. 8, e.l.f. Cosmetics will air a telenovela-inspired campaign with Academy Award-nominated actress Melissa McCarthy, as Dove features 30-second spot ‘The Game is Ours,’ to inspire body confidence in young girls. Separately, Manscaped launches first Super Bowl ad.
HBW Insight - February 4, 2026

Hawaii’s Age Restriction On Supplement Sales Also Would Require Behind-The-Counter Storage
Hawaii proposes age-restricted sales but, unlike similar bills also filed in Alaska, Massachusetts, Michigan and Washington legislatures, would require behind-the-counter storage to limit consumer access in stores.
HBW Insight - February 4, 2026

France Gives Go-Ahead For Private-Equity Buyout Of Biogaran – But With Strings
BC Partners has completed its acquisition from Servier of French generics giant Biogaran after the French government allowed the private-equity takeover on condition that BPI France take a minority stake. Meanwhile, former Biogaran CEO Erick Roche has returned to the role after a long stint at Teva.
Generics Bulletin - February 3, 2026

Samsung Bioepis Settles Global Launches For Its Eylea Biosimilar
Just a few days after Alvotech announced global settlements for its Eylea rival, Samsung Bioepis has followed up with its own agreements with the originators.
Generics Bulletin - February 3, 2026

Teva Dishes On Plans To File Olanzapine LAI In Europe
Teva is lining up Europe as the next regulatory market for its long-acting injectable olanzapine, following its US filing late last year, as the company looks to build a global schizophrenia franchise.
Generics Bulletin - February 3, 2026

Cell And Gene Therapy Enters ‘Disciplined Growth Cycle’ As Commercial Momentum Builds
Cell and gene therapy is shifting into a new phase, as maturing commercial launches, rising big pharma participation and regulatory momentum replace hype and skepticism.
In Vivo - February 3, 2026